Fig. 2From: Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNPAssessment of respiratory function and impedance in patients with mild to moderate asthma. Changes in respiratory function by spirometry (A) and changes in respiratory resistance by FOT (B) at 3 months and 1 year after dupilumab administration are shown. Pre and 3 month: n = 50, 1 year: n = 18. Each panel shown represents the mean ± SD. *p < 0.05, **p < 0.01 by student’s t testBack to article page